HER2-Mutated NSCLC: Second-Line Treatment Selection and Emerging Approaches

In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.

The American Society of Clinical Oncology and the Community Oncology Alliance released new Oncology Medical Home standards that are designed to help guide care providers as they treat patients.

In an interview with Targeted Oncology, David W. Dougherty, MD, discussed how the COVID-19 pandemic has changed the cancer care space.

Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.